Quantra vs TEG for Congenital Cardiac Surgery - a Pilot Validation Study

Comparison of the Point-of-care Coagulation Device Quantra With the TEG for Congenital Cardiac Surgery - a Pilot Validation Study

Congenital heart surgery on cardio-pulmonary bypass (CPB) is associated with impacted coagulation quality and increased bleeding after separation of CPB.

The current testing device used at our institution is the "TEG 5000" (Haemonetics Corporation). The novel coagulation testing device "Quantra System" (Hemosonics) has favorable properties (result within 20 minutes) allowing for a quicker identification of the coagulation problem and hence faster administration of the correct coagulation products, potentially leading to better coagulation quality and possibly reducing the need of additional blood products. The aim of this prospective observational (non-interventional, investigational only) quality improvement study is to investigate if the Quantra is reliable and valid in predicting the coagulation status when compared with our standard-of-care device TEG 5000.

Study Overview

• Status: Completed
• Conditions: Coagulopathy
• Intervention / Treatment: Device: Correlation of the Quantra with the TEG

Detailed Description

Congenital heart surgery on cardio-pulmonary bypass (CPB) is associated with impacted coagulation quality and increased bleeding after separation of CPB. Therefore, coagulation products and blood products often need to be given/transfused during these cases. The correct choice and dosing of coagulation products is essential to effectively stop bleeding and reduce the need of additional blood transfusion.

The current testing device used at our institution during congenital heart surgery on CPB is the TEG 5000 (Haemonetics Corporation). Prior to separation from CPB (mostly 30-60 minutes) and after the first coagulation products were given (approx. 60 minutes after separation from CPB) a Clauss Fibrinogen and a TEG are drawn. These samples are sent to an off-site lab for processing and time to result ranges from 60-90 minutes. Therefore, results are often not present when needed.

An easy to use point-of-care (POC) test device being readily available in the operation room and allowing for rapid results could result in quicker identification of the coagulation problem and hence allow for faster administration of the correct coagulation products, potentially leading to better coagulation quality and possibly reducing the need of additional blood products.

The Quantra System (Hemosonics) is an easy-to-use, stand-alone device presenting results within 20 minutes. With these properties all above mentioned problems would be addressed. To date the Quantra has not been used and has not been evaluated in patients with congenital heart disease for cardiac surgery on CPB.

The aim of this prospective observational (non-interventional, investigational only) quality improvement study is to investigate if the Quantra is reliable and valid in predicting the coagulation status when compared with our standard-of-care device TEG

All patients who are enrolled in this study will be patients who are scheduled to undergo cardiac surgery and who require a general anesthesia, endotracheal intubation, arterial line placement and coagulation testing as part of standard of care for the surgery.

No patient will have a general anesthesia, endotracheal intubation, arterial line inserted or coagulation testing for research purposes only.

If the family/patient consent to be enrolled in the study the patient will be included in the study. It is standard of care to draw blood samples for coagulation testing (TEG and Clauss Fibrinogen) prior to separation of cardio-pulmonary-bypass (t1) and after the first coagulation products were given (t2), resulting in 2 x 5.4mL of blood.

For testing of efficacy/reliability/validity of the Quantra System we will need to draw additional blood samples (2.7mL) for each time point t1 and t2, resulting in a total of 2 x 2.7mL. These extra 5.4mL of blood drawn during the research portion of this study is additional to what they need for the surgical procedure and is not standard of care.

No clinical decision will be made on the results of the Quantra System. This is an investigational, non-interventional study.

• Study Type: Observational
• Enrollment (Actual): 40

Contacts and Locations

Study Locations

• United States
  • California
    • Palo Alto, California, United States, 94305
      • Stanford University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 8 years (Child)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients with congenital heart disease scheduled for cardiac surgery on cardio-pulmonary bypass at our institution Age range is 0 to 8 years. There are no enrollment restrictions related to gender or ethnic background.

Description

Inclusion Criteria:

• All cases with hypothermia (<=30C)

Exclusion Criteria:

• Neonatal/Infant Bloodless surgery
• Bodyweight under 3kg

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation Quantra vs TEG_Fibrinogen_Function1	Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with TEG (K time & alpha angle)	30 minutes during anesthesia, prior to separation from CPB
Correlation Quantra vs TEG_Fibrinogen_Function1	Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with TEG (K time & alpha angle)	30 minutes during anesthesia, after coagulation products were given
Correlation Quantra vs TEG_Fibrinogen_Function2	Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with Clauss Fibrinogen.	30 minutes during anesthesia, prior to separation from CPB
Correlation Quantra vs TEG_Fibrinogen_Function2	Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with Clauss Fibrinogen.	30 minutes during anesthesia, after coagulation products were given
Correlation Quantra vs TEG_Platelet_Function	Correlation/Linear regression/normal_vs_abnormal of Quantra (CS/PCS) with TEG (MA)	30 minutes during anesthesia, prior to separation from CPB
Correlation Quantra vs TEG_Platelet_Function	Correlation/Linear regression/normal_vs_abnormal of Quantra (CS/PCS) with TEG (MA)	30 minutes during anesthesia, after coagulation products were given
Correlation Quantra vs TEG_clot initiation	Correlation/Linear regression/normal_vs_abnormal of Quantra (CT/CTH) with TEG (R time)	30 minutes during anesthesia, prior to separation from CPB
Correlation Quantra vs TEG_clot initiation	Correlation/Linear regression/normal_vs_abnormal of Quantra (CT/CTH) with TEG (R time)	30 minutes during anesthesia, after coagulation products were given
Correlation Quantra vs TEG_clot strength/firmness	Correlation/Linear regression/normal_vs_abnormal of Quantra (CS) with TEG (G value)	30 minutes during anesthesia, prior to separation from CPB
Correlation Quantra vs TEG_clot strength/firmness	Correlation/Linear regression/normal_vs_abnormal of Quantra (CS) with TEG (G value)	30 minutes during anesthesia, after coagulation products were given

Collaborators and Investigators

• Sponsor: Stanford University
• Investigators: Principal Investigator: Alexander R Schmidt, MD, Stanford University

Publications and helpful links

General Publications

• Ochocinski D, Navaratnam M, Babb A, De Souza E, Kamra K, Sleasman JR, Margetson TD, Bhamidipati JK, Ramamoorthy C, Schmidt AR. Comparison of the Point-Of-Care Coagulation Device Quantra With the TEG-5000 for Congenital Cardiac Surgery-A Pilot Study. Paediatr Anaesth. 2025 Mar 17. doi: 10.1111/pan.15097. Online ahead of print.

Study record dates

Study Major Dates

• Study Start (Actual): October 13, 2022
• Primary Completion (Actual): May 25, 2023
• Study Completion (Actual): May 25, 2023

Study Registration Dates

• First Submitted: February 28, 2022
• First Submitted That Met QC Criteria: March 15, 2022
• First Posted (Actual): March 25, 2022

Study Record Updates

• Last Update Posted (Actual): May 13, 2025
• Last Update Submitted That Met QC Criteria: May 7, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Blood Coagulation Disorders
• Other Study ID Numbers: Quantra vs TEG

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes